Abstract: Provided are compounds of Formula (I?): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

Abstract: Embodiments of systems and methods for enhanced drift remediation with causal methods and online model modification are described. In some embodiments, an Information Handling System (IHS) may include a processor and a memory coupled to the processor, the memory having program instructions stored thereon that, upon execution, cause the IHS to: detect drift in an Artificial Intelligence (AI) or Machine Learning (ML) model configured to make a prediction or a causal reasoning graphical or structural inference based upon input data, identify a root cause of the drift, and tag the input data with an indication of the root cause.

Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:

Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signaling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.

Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:

Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:

Abstract: In an embodiment of the invention, a method of measuring bone density is provided comprising: irradiating a volume to be analyzed; for x-rays emerging from the irradiated volume, detecting at least two of transmitted x-rays, forward scattered x-rays and backward scattered x-rays; and analyzing at least two of the transmitted x-rays, the forward scattered x-rays, or the backward scattered x-rays to determine a density by determining at least one of a ratio of the forward scattered x-rays to the backward scattered x-rays, a ratio of the forward scattered x-rays to the transmitted x-rays, or the product of the ratio of the forward scattered x-rays to the backward scattered x-rays and the ratio of the forward scattered x-rays to the transmitted x-rays.

Abstract: The present invention relates to uses of the compounds of Formula I as well as pharmaceutically acceptable salts and stereoisomers thereof in methods to treat a variety of tumors in mammals involving abnormal tyrosine kinase signalling, the compounds represented as: wherein R1 and R2 are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ1Z2, wherein Z1 and Z2 are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S, and the aryl and heteroaryl may be further substituted with halogen, alkyl, alkenyl, and alkynyl; with the proviso that when R1 is hydrogen, R2 is a group other than hydrogen.

Abstract: The present invention relates to compounds of the Formula I, the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals: wherein n is an integer, preferably n is 1; wherein R1 and R2 are independently selected from the group consisting of:

Abstract: The present invention provides a contactor apparatus and method for removing solvent from a polymer cement. The resulting polymer is substantially free of solvent and exhibits improved porosity and more uniform particle size distribution. In one embodiment, a contactor apparatus consists of a cylindrical casing having a high pressure section, a convergence section, a high velocity section, a divergence section, and a discharge section. The polymer cement is introduced into the high pressure section to significantly and unexpectedly improve solvent removal. The convergence and divergence sections preferably have cross-sectional areas that correspond to an effective angle from about 4° to about 65°. The polymer cement is mixed with high pressure steam. After converging, the polymer cement forms more uniform droplets due to high shear of steam. In the divergence and discharge sections, the polymer is substantially devolatized.

Abstract: The present invention provides a contactor apparatus and method for removing solvent from a polymer cement. The resulting polymer is substantially free of solvent and exhibits improved oil absorption and lower fines. In one aspect, a contactor is provided comprising a cylindrical casing having a high pressure section, a convergence section, a high velocity section, a divergence section, and a discharge section. The polymer cement is introduced into the high pressure section to significantly and unexpectedly improve solvent removal. The convergence and divergence sections have cross-sectional areas that correspond to an effective angle from about 4° to about 65°, such as 6°. The polymer cement is mixed with high pressure steam. After converging, the polymer cement forms more uniform droplets due to high shear of steam. In the divergence and discharge sections, the polymer is substantially devolatized.

Abstract: This invention relates to the use of a synergistic nucleating package to promote the rapid crystallization of polymers from the melt. This facilitates the ease of fabrication of extruded or molded articles or otherwise shaped objects formed from the melt, including pelleted product from extrusion.

Abstract: The present invention provides a contractor apparatus and method for removing solvent from a polymer cement. The resulting polymer is substantially free of solvent and exhibits improved oil absorption and lower fines. In one aspect, a contractor is provided including a cylindrical casing having a high pressure section, a convergence section, a high velocity section, a divergence section, and a discharge section. The polymer cement is introduced into the high pressure section to significantly and unexpectedly improve solvent removal. The convergence and divergence sections have cross-sectional areas that correspond to an effective angle from about 4° to about 65°, such as 6°. The polymer cement is mixed with high pressure steam. After converging, the polymer cement forms more uniform droplets due to high shear of steam. In the divergence and discharge sections, the polymer is substantially devolatized.